• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

New recommendations on meningococcal vaccines

Article

The American Academy of Pediatrics has updated its 2011 policy statement on meningococcal vaccines for children and adolescents to include 2 subsequently licensed conjugate vaccines for use in infants.

 

The American Academy of Pediatrics (AAP) has updated its 2011 policy statement on meningococcal vaccines for children and adolescents to include 2 subsequently licensed conjugate vaccines for use in infants.

Special Report: Meeting the challenge of vaccine costs

The new policy statement adds recommendations for immunizing high-risk infants aged as young as 2 months with the quadrivalent MenACWY-CRM (Menveo) vaccine, licensed in 2013, or the bivalent HibMenCY-TT (MenHibrix) vaccine, licensed in 2012, which is also approved for Haemophilus influenzae type b (Hib). The AAP doesn’t recommend routinely vaccinating healthy children aged 2 months to 10 years who aren’t at high risk of meningococcal disease.

The vaccines are given in a 4-dose primary series to children aged between 2 and 18 months who are at increased risk of invasive meningococcal disease because they have persistent complement deficiency (C3, C5-C9, properdin, factor H, or factor D) or functional or anatomic asplenia, or if they are part of a community outbreak. Infants at risk because of travel to an area with hyperendemic or epidemic meningococcal disease should receive the quadrivalent rather than the bivalent vaccine.

Children aged 2 months to 6 years who are at persistent risk should receive a booster dose 3 years after the primary vaccine series and every 5 years thereafter.

HibMenCY-TT also can be used for routine vaccination against Hib. If it is given to protect against meningococcal disease, it should be used for all 4 doses of Hib vaccine, and other Hib vaccines should be avoided.

To get weekly clinical advice for today's pediatrician, subscribe to the Contemporary Pediatrics eConsult.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.